FIGURE 7 from Dual Blockade of EP2 and EP4 Signaling is Required for Optimal Immune Activation and Antitumor Activity Against Prostaglandin-Expressing Tumors
posted on 2023-08-08, 14:20authored byBrian J. Francica, Anja Holtz, Justine Lopez, David Freund, Austin Chen, Dingzhi Wang, David Powell, Franciele Kipper, Dipak Panigrahy, Raymond N. Dubois, Chan C. Whiting, Peppi Prasit, Thomas W. Dubensky
Effective antagonism of PGE2 signaling modulates significant transcriptional shifts in the TME. A, Volcano plots of selected genes. Blue coloration represents significantly (Padj < 0.05) downregulated genes while red correlation represents significantly upregulated genes. Genes in gray did not meet the significance cutoff. B, Heat map depicting significantly upregulated gene sets from GSEA performed on RNA sequencing analysis above and representative GSEA plot from IFNγ signature. All results represent data from one experiment with 4 animals per group. *** indicates FDR < 0.25 for that gene set compared with vehicle-treated animals.
Funding
Tempest Therapeutics
History
ARTICLE ABSTRACT
Prostaglandin (PGE2) drives tumor progression but the pathway has not been effectively drugged. We demonstrate significantly enhanced immunologic potency and antitumor activity through blockade of EP2 and EP4 PGE2 receptor signaling together with a single molecule.